Literature DB >> 9368538

Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA.

R P Verkooyen1, N A Van Lent, S A Mousavi Joulandan, R J Snijder, J M van den Bosch, H P Van Helden, H A Verbrugh.   

Abstract

The incidence of Chlamydia pneumoniae infection was determined in patients with chronic obstructive pulmonary diseases (COPD) by prospective serial serology. Chlamydia-specific IgG, IgM and IgA antibodies were detected with a recombinant DNA lipopolysaccharide (LPS) ELISA as well as with a micro-immunofluorescence (MIF) assay with C. pneumoniae elementary bodies. From 271 consecutive COPD patients who visited the outpatient clinic of the department of pulmonary diseases (211 males, 60 females, age range 34-88 years, mean age 66 SD 10 years), blood samples (n = 1058) were taken every 2-7 months; the observation period ranged from 3 to 19 months (mean 15 SD 4). The prevalence of chlamydial IgG was 72% with the MIF and 53% with the rDNA LPS ELISA. More than 90% of the COPD patients had no significant changes in their chlamydia-specific IgG, IgA and IgM titres in either test during the observation period. Seven (3%) patients had MIF results indicating acute C. pneumoniae infection during their surveillance period, of whom five were confirmed by rDNA LPS ELISA. Eleven (4%) additional patients were infected during observation, as determined by rDNA LPS ELISA only. These patients had significantly elevated C. pneumoniae-specific IgG and IgA MIF titres, as compared with the patients without infection. All 18 patients with serological evidence of acute infection during their surveillance period were re-tested in a commercial MIF test that can distinguish between C. pneumoniae, C. trachomatis and C. psittaci LPS-specific antibodies, but no evidence of C. trachomatis or C. psittaci infection was found. The incidence of chlamydial infection was 2.2 and 5.3/100 person-years, when diagnosed by MIF and rDNA LPS ELISA, respectively. It is concluded that the rDNA LPS chlamydia assay may currently be the most sensitive serological tool for diagnosing recent respiratory chlamydia infections and that C. pneumoniae infection occurs frequently in COPD patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368538     DOI: 10.1099/00222615-46-11-959

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

1.  Long term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery disease.

Authors:  K Sadamatsu; H Shimokawa; H Tashiro; K Yamamoto
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

2.  Beta blockers enhance early diastolic filling in ischaemic heart disease: a radionuclide assessment.

Authors:  E Moralidis; G McCurrach; W Martin; I Hutton
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

3.  Dilated cardiomyopathy and Chlamydia pneumoniae infection.

Authors:  H Song; H Tasaki; A Yashiro; K Yamashita; T Toyokawa; Y Nagai; H Takatsu; H Taniguchi; Y Nakashima
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

4.  Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence.

Authors:  P Garnett; O Brogan; C Lafong; C Fox
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

5.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies.

Authors:  A Tiran; R A Tio; J M Ossewaarde; B Tiran; P den Heijer; T H The; M M Wilders-Truschnig
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Newly characterized species-specific immunogenic Chlamydophila pneumoniae peptide reactive with murine monoclonal and human serum antibodies.

Authors:  Eric L Marston; Andrea V James; J Todd Parker; John C Hart; Teresa M Brown; Trudy O Messmer; Danny L Jue; Carolyn M Black; George M Carlone; Edwin W Ades; Jacquelyn Sampson
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 8.  Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease.

Authors:  A J White; S Gompertz; R A Stockley
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

9.  Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.

Authors:  R P Verkooyen; D Willemse; S C Hiep-van Casteren; S A Joulandan; R J Snijder; J M van den Bosch; H P van Helden; M F Peeters; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

10.  Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Levent Erkan; Oguz Uzun; Serhat Findik; Didem Katar; Ahmet Sanic; Atilla G Atici
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.